Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2012-07-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jama.2012.7625PMID 22797642
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975–2009)

  2012influential reference
• A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.

  2012cited by this paper
• Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study

  2011cited by this paper
• Surveillance bias in outcomes reporting.

  2011cited by this paper
• Nonexperimental comparative effectiveness research using linked healthcare databases.

  2011cited by this paper
• Comparing treatments using observational study designs: what can we do about selection bias?

  2010cited by this paper
• Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

  2010cited by this paper
• The natural history of secondary progressive multiple sclerosis

  2010cited by this paper
• Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.

  2009cited by this paper
• Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator

  2009cited by this paper
• Impact of multiple sclerosis relapses on progression diminishes with time

  2009cited by this paper
• HOW EFFECTIVE ARE DISEASE-MODIFYING DRUGS IN DELAYING PROGRESSION IN RELAPSING-ONSET MS?. Authors' reply

  2008cited by this paper
• Immortal time bias in the study of effectiveness of interferon‐β in multiple sclerosis

  2008cited by this paper
• Confounders in natural history of interferon‐β–treated relapsing multiple sclerosis

  2008cited by this paper
• HOW EFFECTIVE ARE DISEASE-MODIFYING DRUGS IN DELAYING PROGRESSION IN RELAPSING-ONSET MS?

  2008cited by this paper
• Disability as an outcome in MS clinical trials

  2008cited by this paper
• Relapses in multiple sclerosis are age- and time-dependent

  2008cited by this paper
• Beyond health care--socioeconomic status and health.

  2008cited by this paper
• Natural history of secondary-progressive multiple sclerosis

  2008cited by this paper
• Interferon‐β treatment and the natural history of relapsing‐remitting multiple sclerosis

  2008cited by this paper
• How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?

  2007cited by this paper
• New natural history of interferon‐β–treated relapsing multiple sclerosis

  2007cited by this paper
• New natural history of interferon-beta-treated relapsing multiple sclerosis.

  2007cited by this paper
• Immortal time bias in observational studies of drug effects

  2007cited by this paper
• Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS

  2006cited by this paper
• How much can we learn from long-term extension trials in multiple sclerosis?

  2006cited by this paper
• Is late-onset multiple sclerosis associated with a worse outcome?

  2006cited by this paper
• Disability progression in multiple sclerosis is slower than previously reported

  2006cited by this paper
• Long‐term clinical experience with weekly interferon beta‐1a in relapsing multiple sclerosis

  2006cited by this paper
• The natural history of primary progressive MS in British Columbia, Canada

  2005cited by this paper
• Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience

  2005cited by this paper
• Interferons in relapsing remitting multiple sclerosis: a systematic review.

  2003cited by this paper
• A post-marketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients

  2003cited by this paper
• Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy

  2003cited by this paper
• Neutralising antibodies to interferon beta during the treatment of multiple sclerosis

  2002cited by this paper
• A 6‐year clinical and MRI follow‐up study of patients with relapsing–remitting multiple sclerosis treated with Interferon‐beta

  2002cited by this paper
• Trends in mortality by neighbourhood income in urban Canada from 1971 to 1996

  2002cited by this paper
• Interferon beta‐1b treatment in patients with relapsing–remitting multiple sclerosis under a standardized protocol in Spain

  2000cited by this paper
• Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts

  2000cited by this paper
• Can it work? Does it work? Is it worth it?

  1999cited by this paper
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  1998cited by this paper
• Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

  1992cited by this paper
• Life expectancy in patients attending multiple sclerosis clinics

  1992cited by this paper
• Scales for rating impairment in multiple sclerosis

  1988cited by this paper
• The Role of a Second Control Group in an Observational Study

  1987cited by this paper
• Prevalence of Multiple Sclerosis in British Columbia

  1986cited by this paper
• Sample-size formula for the proportional-hazards regression model.

  1983cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper

• Simultaneously Dealing With Immortal Time Bias and Residual Confounding: A Case Study of a High‐Dimensional Propensity Score Approach With a Nested Case–Control Framework in Multiple Sclerosis Research

  2025cites this paper
• The molecular dynamics simulation of coronavirus- based compound (6OHW structure) interaction with interferon beta-1a protein at different temperatures and pressures: Virus destruction process

  2024cites this paper
• Breaking down the cellular responses to type I interferon neurotoxicity in the brain

  2023cites this paper
• Multiple sclerosis in the elderly: a retrospective cohort study

  2023cites this paper
• Using instrumental variables to correct for bias in real-world cohort studies of the effects of disease-modifying treatment in MS

  2023cites this paper
• Relationship of Motor Impairment with Cognitive and Emotional Alterations in Patients with Multiple Sclerosis

  2023cites this paper
• The adaptation model of immunity: A new insight into aetiology and treatment of multiple sclerosis

  2023cites this paper
• The protective role of interaction between vitamin D, sex hormones and calcium in multiple sclerosis

  2022cites this paper
• Quality of observational studies of clinical interventions: a meta-epidemiological review

  2022cites this paper
• The Neuroimmunology of Multiple Sclerosis: Fictions and Facts

  2022cites this paper
• DNND_A_370173 111..125

  2022cites this paper
• Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis.

  2022cites this paper
• The Wahls Behavior Change Model for Complex Chronic Diseases: A Clinician’s Guide

  2022cites this paper
• Cumulative effects of therapies on disability in relapsing multiple sclerosis

  2021cites this paper
• The Multiple Sclerosis Treatment Optimization Program

  2021cites this paper
• Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada

  2021cites this paper
• Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study

  2021cites this paper
• Averting multiple sclerosis long-term societal and healthcare costs: the Value of Treatment (VoT) project

  2021cites this paper
• A non-parametric propensity score for estimating the effect of interferon-beta or glatiramer acetate on long-term outcomes of multiple sclerosis.

  2021cites this paper
• NAverting multiple sclerosis long-term societal and healthcare costs: The Value of Treatment (VoT) project.

  2021cites this paper
• Improving quality, affordability, and equity of multiple sclerosis care

  2021cites this paper
• Targeted Krüppel-Like Factor 4 Gene Knock-Out in Retinal Ganglion Cells Improves Visual Function in Multiple Sclerosis Mouse Model

  2020influential citation
• Multiple sclerosis

  2020cites this paper
• Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes

  2020cites this paper
• Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.

  2020cites this paper
• Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) – preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial

  2020cites this paper
• SARS-CoV-2, multiple sclerosis, and focal deficit in a postpartum woman: A case report.

  2020cites this paper
• The retirement rate due to multiple sclerosis has decreased since 1995- A retrospective study in a Finnish central hospital.

  2020cites this paper
• Gene Therapy with Single-Subunit Yeast NADH-Ubiquinone Oxidoreductase (NDI1) Improves the Visual Function in Experimental Autoimmune Encephalomyelitis (EAE) Mice Model of Multiple Sclerosis (MS)

  2020cites this paper
• Evaluation of Serum Interleukin-10, Tumor Necrosis Factor Alpha Level and Cardiovascular Autonomic Functions in Multiple Sclerosis Patients

  2020cites this paper
• Long‐term effect of first‐line injectable multiple sclerosis treatments: Input of a time‐dependent propensity score

  2020cites this paper
• Long-term Follow-up of Relapsing-Remitting Multiple Sclerosis

  2020cites this paper
• Real-world studies provide reliable comparisons of disease modifying therapies in MS – No

  2020cites this paper
• Vaccination in multiple sclerosis - Challenging practices (Review).

  2020cites this paper
• Determinants of disability development in patients with multiple sclerosis

  2020cites this paper
• Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis

  2020cites this paper
• A Modified MCT-Based Ketogenic Diet Increases Plasma β-Hydroxybutyrate but Has Less Effect on Fatigue and Quality of Life in People with Multiple Sclerosis Compared to a Modified Paleolithic Diet: A Waitlist-Controlled, Randomized Pilot Study

  2020cites this paper
• The long-term effects of disease modifying therapies on disability in people living with multiple sclerosis: A systematic review and meta-analysis.

  2019cites this paper
• Long-term disability outcomes in relapsing-remitting multiple sclerosis: a 10-year follow-up study

  2019cites this paper
• Interferon beta: Medication which started the revolution in the treatment of multiple sclerosis

  2019cites this paper
• Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis

  2019cites this paper
• Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.

  2019cites this paper
• Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis

  2019cites this paper
• Relating Treatment Effect on Relapses with Disability Worsening in Multiple Sclerosis Patients: Age Matters

  2019cites this paper
• Potential Benefits of Early Aggressive Treatment in Multiple Sclerosis.

  2019cites this paper
• Neuroprotection in Miscellaneous Neurological Disorders

  2019cites this paper
• Immunotherapy prevents long-term disability in relapsing multiple sclerosis over 15 years

  2019cites this paper
• Treatment strategies in multiple sclerosis : current and future practice considerations

  2019cites this paper
• Identification of brain antigens recognized by autoantibodies in experimental autoimmune encephalomyelitis-induced animals treated with etomoxir or interferon-β

  2018cites this paper
• Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study

  2018cites this paper
• Fractional anisotropy of white matter, disability and blood iron parameters in multiple sclerosis

  2018cites this paper
• Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme

  2018cites this paper
• A Kv1.3 channel‐specific blocker alleviates neurological impairment through inhibiting T‐cell activation in experimental autoimmune encephalomyelitis

  2018cites this paper
• Comparison of statistical approaches dealing with time-dependent confounding in drug effectiveness studies

  2018cites this paper
• Characterization of annual disease progression of multiple sclerosis patients: A population-based study

  2018cites this paper
• Design, synthesis and evaluation of an anthraquinone derivative conjugated to myelin basic protein immunodominant (MBP85-99) epitope: Towards selective immunosuppression.

  2018cites this paper
• Multiple sclerosis: treatment, monitoring, activity and disability

  2018cites this paper
• Early versus later treatment start in multiple sclerosis: a register‐based cohort study

  2018cites this paper
• Disability progression in multiple sclerosis: a Tunisian prospective cohort study

  2018cites this paper
• Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis

  2018cites this paper
• Disease-modifying therapies for multiple sclerosis

  2018cites this paper
• Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis

  2018cites this paper
• Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate.

  2018cites this paper
• Information provision for people with multiple sclerosis.

  2018cites this paper
• Validation of an algorithm to detect severe MS relapses in administrative health databases.

  2018cites this paper
• Impact of Pilates Exercise in Multiple Sclerosis: A Randomized Controlled Trial.

  2018cites this paper
• Combination treatment of docosahexaenoic acid (DHA) and all-trans-retinoic acid (ATRA) inhibit IL-17 and RORγt gene expression in PBMCs of patients with relapsing-remitting multiple sclerosis

  2018cites this paper
• Predicting risk of secondary progression in multiple sclerosis: A nomogram

  2018cites this paper
• Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a

  2017cites this paper
• Comparing the efficacy of disease-modifying therapies in multiple sclerosis.

  2017cites this paper
• Co‐Delivery of Disease Associated Peptide and Rapamycin via Acetalated Dextran Microparticles for Treatment of Multiple Sclerosis

  2017cites this paper
• Estimating inverse probability weights using super learner when weight‐model specification is unknown in a marginal structural Cox model context

  2017cites this paper
• Treatment decisions in multiple sclerosis — insights from real-world observational studies

  2017cites this paper
• Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study

  2017cites this paper
• Drug Delivery Strategies for Tolerogenic Therapy for Autoimmune Diseases in an Antigen-Specific Manner

  2017cites this paper
• ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis

  2017cites this paper
• Methods for time‐varying exposure related problems in pharmacoepidemiology: An overview

  2017cites this paper
• Multiple Sclerosis: Immunopathology and Treatment Update

  2017cites this paper
• Evaluating the safety of β-interferons in MS

  2017influential citation
• A Multimodal, Nonpharmacologic Intervention Improves Mood and Cognitive Function in People with Multiple Sclerosis

  2017cites this paper
• On the application of statistical learning approaches to construct inverse probability weights in marginal structural Cox models: Hedging against weight-model misspecification

  2017influential citation
• Age Related Multiple Sclerosis Severity Score: Disability ranked by age

  2017cites this paper
• Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS – NO

  2017cites this paper
• Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar

  2017cites this paper
• Hospitalization is associated with subsequent disability in multiple sclerosis.

  2017cites this paper
• Importance of early treatment initiation in the clinical course of multiple sclerosis

  2017cites this paper
• Correlation Between Neurological Deficits and Spinal Cord Pathological Changes in a Mouse Model of Multiple Sclerosis

  2017cites this paper
• Web-Appendix 1 WEB-APPENDIX for “ Comparison of Statistical Approaches Dealing with Immortal Time Bias in Drug Effectiveness Studies ”

  2016cites this paper
• Practice of Epidemiology Comparison of Statistical Approaches for DealingWith Immortal TimeBias in Drug Effectiveness Studies

  2016cites this paper
• Association between the use of selective serotonin reuptake inhibitors and multiple sclerosis disability progression

  2016cites this paper
• Disease modifying therapies for relapsing multiple sclerosis

  2016cites this paper
• Associations of Lifestyle, Medication, and Socio-Demographic Factors with Disability in People with Multiple Sclerosis: An International Cross-Sectional Study

  2016cites this paper
• Cognition, disease activity and MRI changes in early multiple sclerosis

  2016cites this paper
• Does early (treatment in) BENEFIT lead to late MS benefit?

  2016cites this paper
• Assessing Functional Decline in Neurological Diseases Clinical Trials: Duration of Follow-Up - The Case of Multiple Sclerosis.

  2016cites this paper
• Drugs for multiple sclerosis.

  2016cites this paper
• Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.

  2016cites this paper
• Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.

  2016cites this paper
• Multiple Sclerosis Subtypes: How the Natural History of Multiple Sclerosis Was Challenged due to Treatment

  2016cites this paper
• Observational data: Understanding the real MS world

  2016cites this paper